Treatment of Guillain-Barre syndrome with intravenous immunoglobulin

Neurology

Volumn 51, Issue 6 SUPPL. 5, 1998, Pages

  Sater, Richard A ^a   Rostami, Abdolmohamad ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE ANTIBODY; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; PLACEBO;

ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; BRAIN DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMYELINATION; DOSE RESPONSE; DRUG SAFETY; GENETIC SUSCEPTIBILITY; GUILLAIN BARRE SYNDROME; HEPATITIS C; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MOTOR NEURON DISEASE; MULTICENTER STUDY; NEUTROPENIA; PARALYSIS; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; RELAPSE; THROMBOEMBOLISM;

EID: 0032407011     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.51.6_suppl_5.s9     Document Type: Article

References (97)

1. Ropper AH, Wijdicks EFM, Truax BT. Guillain-Barré syndrome. Philadelphia: FA Davis, 1991.
2. Rostami A, Sater RA. Guillain-Barré syndrome. In: Rolak L, Harati Y, eds. Neuroimmunology for the clinician. Boston: Butterworth-Heinemann, 1997:205-228.
3. Arnason B, Soliven B. Acute inflammatory demyelinating polyradiculoneuropathy. In: Dyck P, Thomas PK, Griffin JW, Low PA, Poduslo J, eds. Peripheral neuropathy, 2. Philadelphia: WB Saunders, 1993:1437-1497.
4. Alter M. The epidemiology of Guillain-Barré syndrome. Ann Neurol 1990;27:S7-12.
5. Samantray SK, Johnson SC, Mathai KV, Pulimood BM. Landry-Guillain-Barré-Strohl syndrome. A study of 302 cases. Med J Aust 1977;2:84-91.
6. Landry O. Note sur la paralysie ascendante aigue. Gazette Hebdomadaire 1859;6:472-474.
7. Guillain G, Barré JA, Strohl A. Sur un syndrome de radiculonevrite avec hyperalbuminose du liquide cephalo-rachidien sans les caracteres clinques et graphiques des reflexes tendineux. Bull Memories Soc Medicale Hôpitaux Paris 1916;40: 1462-1470.
8. Cornblath DR. Electrophysiology in Guillain-Barré syndrome. Ann Neurol 1990;27:S17-20.
9. Guillain-Barré Study Group. Plasmapheresis and acute Guillain-Barré Syndrome. Neurology 1985;35:1096-1104.
10. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987; 22:753-761.
11. van der Meche FGA, Schmitz PIM, and the Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré Syndrome. N Engl J Med 1992;326:1123-1129.
12. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of opthalmoplegia, ataxia and areflexia). N Engl J Med 1956;255:57-65.
13. Berlit P, Rakicky J. The Miller-Fisher syndrome: review of the literature. J Clin Neuroopthalmol 1992;12:57-63.
14. Ropper AH. Further regional variants of acute immune polyneuropathy. Arch Neurol 1994;51:671-675.
15. Ropper AH. Unusual clinical variants and signs in Guillain-Barré syndrome. Arch Neurol 1986;43:1150-1152.
16. Young RR, Asbury AK, Adams RD. Pure pan-dysautonomia with recovery. Description and discussion with diagnostic criteria. Brain 1975;98:613-636.
17. McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 1993;33:333-342.
18. Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China: relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995;118:597-605.
19. Feasby TE. Axonal Guillain-Barré syndrome. Muscle Nerve 1994;17:678-679.
20. Vriesendorp FJ, Mishu B, Blaser MJ, Koski CL. Serum antibodies to GM1, GD1b, peripheral nerve myelin, and Campylobacter jejuni in patients with Guillain-Barré syndrome and controls: correlation and prognosis. Ann Neurol 1993;34:130-134.
21. Krucke W. Die primar-entzundliche Polyneuritis unbekannter Ursache. In: Lubarsch O, Henke F, Rossle G, eds. Handbuch des speziellen pathologischen Anatomie und Histologie. Berlin: Springer-Verlag, 1955.
22. Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Medicine 1969;48:173-215.
23. Prineas JW. Acute idiopathic polyneuritis: an electron microscope study. Lab Invest 1972;26:133-147.
24. Waksman BH, Adams RD. Allergic neuritis: an experimental disease of rabbits induced by the injection of peripheral nervous tissue and adjuvants. J Exp Med 1955;102:213-235.
25. Rostami AM. P2-reactive T cells in inflammatory demyelination of the peripheral nerve. J Infect Dis 1997;176:S160-163.
26. Rostami AM. Guillain-Barré syndrome: clinical and immunologic aspects. Springer Semin Immunopathol 1995;17:29-42.
27. Sharief MK, McLean B, Thompson EJ. Elevated serum levels of tumor necrosis factor-alpha in Guillain-Barré syndrome. Ann Neurol 1993;33:591-596.
28. Exley AR, Smith N, Winer JB. Tumor necrosis factor-alpha and other cytokines in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1994;57:1118-1120.
29. Weller M, Stevens A, Sommer N, Melms A, Dichgans J, Wietholter H. Comparative analysis of cytokine patterns in immunological, infectious and oncologic neurologic disorders. J Neurol Sci 1991;104:215-221.
30. Sharief MK, Ingram DA, Swash M. Circulating tumor necrosis factor-alpha correlates with electrodiagnostic abnormalities in Guillain-Barré syndrome. Ann Neurol 1997;42:68-73.
31. Sivieri S, Ferrarini AM, Lolli F, et al. Cytokine pattern in the cerebrospinal fluid from patients with GBS and CIDP. J Neurol Sci 1997;147:93-95.
32. Sindern E, Schweppe K, Ossege LM, Malin JP. Potential role of transforming growth factor-beta 1 in terminating the immune response in patients with Guillain-Barré syndrome. J Neurol 1996;243:264-268.
33. Pestronk A, Chaudhry V, Feldman EL, et al. Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities and high titers of antiglycolipid antibodies. Ann Neurol 1990;27:316-326.
34. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-GQ1b IgG antibody is associated with opthalmoplegia in Miller-Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology 1993;43:1911-1917.
35. Irie S, Saito T, Kanazawa N, et al. Relationships between anti-ganglioside antibodies and clinical characteristics of Guillain-Barré syndrome. Intern Med 1997;36:607-612.
36. Visser LH, Van der Meche FGA, Van Doom PA, et al. Guillain-Barré syndrome without sensory loss (acute motor neuropathy): a subgroup with specific clinical, electrodiagnostic and laboratory features. Brain 1995;118:841-847.
37. Daune GC, Farrer RG, Dalakas MC, Quarles RH. Sensory neuropathy associated with monoclonal immunoglobulin M to GD1b ganglioside. Ann Neurol 1992;31:683-685.
38. Wicklein EM, Pfeiffer G, Yuki N, Hartard C, Kunze K Prominent sensory ataxia in Guillain-Barré syndrome associated with IgG anti-GD1b antibody. J Neurol Sci 1997;151:227-229.
39. Yuki N, Sato S, Tsuji S, Ohsana T, Miyatake T. Frequent presence of anti-GQ1b antibody in Fisher syndrome. Neurology 1993;43:414-417.
40. Yuki N, Taki T, Takahashi M, et al. Molecular mimicry between GQ(1b) ganglioside and lipopolysaccharides of Campylobacter-jejuni isolated from patients with Fisher's syndrome. Ann Neurol 1994;36:791-793.
41. Yuki N, Tada T, Inagaki F, et al. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Med 1993;178:1771-1775.
42. Hafer-Macko C, Hsieh ST, Li CY, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol 1996;40:635-644.
43. Hafer-Macko C, Sheikh K, Li CY, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996;39:625-635.
44. Hughes RAC. Guillain-Barré Syndrome. London: Springer-Verlag, 1990.
45. Hughes RAC, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial of prednisolone in acute polyneuropathy. Lancet 1978;2:750-753.
46. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997;349:225-230.
47. Brettle RP, Gross M, Legg NJ, Lockwood M, Pallis C. Treatment of acute polyneuropathy by plasma exchange [letter]. Lancet 1978;2:1100.
48. Kleyweg RP, van der Meche FGA, Meulstee J. Treatment of Guillain-Barré syndrome with high dose immunoglobulin. Neurology 1988;38:1639-1641.
49. Bril V, Use WK, Pearce R, Dhanani A, Sutton D, Kong K. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology 1996;46:100-103.
50. Vriesendorp FJ, Mayer R, Koski CL. Kinetics of antiperipheral nerve myelin antibody in patients with Guillain Barré syndrome treated and not treated with plasmapheresis. Arch Neurol 1991;48:858-861.
51. Dutch Guillain-Barré Syndrome Study Group. Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. Ann Neurol 1994;35:749-752.
52. Haupt WF, Rosenow F, van der Ven C, Borberg H, Pawlik G. Sequential treatment of Guillain-Barré syndrome with extracorporeal elimination and intravenous immunoglobulin. J Neurol Sci 1996;137:145-149.
53. Uldry PA, Bogousslavsky J, Regli F. Guillain-Barré syndrome in a 93-year-old woman: rapid improvement of neurologic function following intravenous immunoglobulin. Schweiz Arch Neurol Psychiatr 1991;142:301-305.
54. Zafeiriou DI, Kontopoulos EE, Katzos GS, Gombakis NP, Kanakoudi FG. Single dose immunoglobulin therapy for childhood Guillain-Barré syndrome. Brain Dev 1997;19:323-325.
55. Gurses N, Uysal S, Cetinkaya F, Islek I, Kalayci AG. Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Scand J Infect Dis 1995;27:241-243.
56. Reisin RC, Pociecha J, Rodriguez E, Massaro ME, Arroyo HA, Fejerman N. Severe Guillain-Barré syndrome in childhood treated with human immune globulin. Pediatr Neurol 1996; 14:308-312.
57. Arakawa Y, Yoshimura M, Kobayashi S, Ichihashi K. The use of intravenous immunoglobulin in Miller-Fisher syndrome. Brain Dev 1993;15:231-233.
58. Heafield MT, Gammage MD, Nightingale S, Williams AC. Idiopathic dysautonomia treated with intravenous gamma-globulin. Lancet 1996;347:28-29.
59. Mericle RA, Triggs WJ. Treatment of acute pandysautonomia with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 1997;62:529-531.
60. Stangel M, Hartung HP, Marx P, Gold R. Intravenous immunoglobulin treatment of neurological autoimmune diseases. J Neurol Sci 1998;153:203-214.
61. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992;326:107-115.
62. Debre M, Bonnet MC, Fridman WH, et al. Infusion of Fcgamma fragments for therapy of children with acute immune thrombocytopenic purpura. Lancet 1993;342:945-949.
63. Takai T, Ono M, Hikida M, Ohmori H, Ravetch JV. Augmented humoral and anaphylactic responses in Fc gamma RII deficient mice. Nature 1996;379:346-350.
64. Kondo N, Ozawa T, Mushiake K, et al. Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin. J Clin Immunol 1991;11:152-158.
65. Miyagi F, Horiuchi H, Nagata I, et al. Fc portion of intravenous immunoglobulin suppresses the induction of experimental allergic neuritis. J Neuroimmunol 1997;78:127-131.
66. Lundquist I, van Doom PA, Vermeulen M, Brand A. Spontaneous recovery from the Guillain-Barré syndrome is associated with anti-idiotypic antibodies recognizing a cross-reactive idiotype on anti-neuroblastoma cell line antibodies. Clin Immunol Immunopathol 1993;67:192-198.
67. Yuki N, Miyaga F. Possible mechanisms of intravenous immunoglobulin treatment on anti-GM1 antibody mediated neuropathies. J Neurol Sci 1996;139:160-162.
68. Masson PL. Elimination of infectious agents and increase of IgG catabolism as possible mode of action of IVIg. J Autoimmun 1993;6:683-689.
69. Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigen. J Clin Invest 1993;91: 602-607.
70. Svenson M, Hansen MB, Bendtzen K. Binding of cytokines to pharmaceutically prepared human immunoglobulin. J Clin Invest 1993;92:2533-2539.
71. Roitt IM, Brostoff J, Male DK Immunology. St. Louis: CV Mosby, 1993.
72. Frank MM, Basta M, Fries LF. The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin Immunol Immunopathol 1992;62: S82-86.
73. Ballow M, White W, Desbonnet BA. Modulation of in vitro synthesis of immunoglobulin and the induction of suppressor activity by therapy with intravenous immunoglobulin. J Allergy Clin 1989;84:595-602.
74. Ropper AH, Albers JW, Addison R. Limited relapse in Guillain-Barré syndrome after plasma exchange. Arch Neurol 1988;45:314-315.
75. Osterman PO, Fagius J, Safwenberg J, Wikstrom B. Early relapse of acute inflammatory polyradiculoneuropathy after successful treatment with plasma exchange. Acta Neurol Scand 1988;77:273-277.
76. Irani DN, Cornblath DR, Chaudhry V, Borel C, Hanley DF. Relapse in Guillain-Barré syndrome after treatment with human immune globulin. Neurology 1993;43:872-875.
77. Kleyweg RP, van der Meche FG. Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange. J Neurol Neurosurg Psychiatry 1991;54:957-960.
78. Castro LHM, Ropper AH. Human immune globulin infusion in Guillain-Barré syndrome: worsening during and after treatment. Neurology 1993;43:1034-1036.
79. Bleck TP. IVIg for GBS: potential problems in the alphabet soup. Neurology 1993;43:857-858.
80. Visser LH, van der Meche FG, Meulstee J, van Doom PA. Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome. Dutch Guillain-Barré study group. J Neurol Neurosurg Psychiatry 1998;64:242-244.
81. NIH Consensus Conference. Intravenous immunoglobulin. Prevention and treatment of disease. JAMA 1990;264:3189-3193.
82. Ratko TA, Burnett DA, Foulke GE, Matuszewski KA, Sacher RA. University Consortium Expert Panel 1995. Recommendations for off-label use of intravenously administered immunoglobulin preparation. JAMA 1995;273:1865-1870.
83. Misbah SA, Chapel HM. Adverse effects of intravenous immunoglobulin. Drug Safety 1993;9:254-262.
84. Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. N Engl J Med 1986;314:560-564.
85. Misbah S. Intravenous immunoglobulin in the Guillain-Barré syndrome. Products with low IgA content may be used in patients with total IgA deficiency [letter]. Br Med J 1996;313: 1400.
86. Cassidy JT, Nordby GL. Human serum immunoglobulin concentrations: prevalence of immunoglobulin deficiencies. J Allergy Clin Immunol 1975;55:35-48.
87. Ellie E, Combe C, Ferrer X. High-dose intravenous immune globulin and acute renal failure. N Engl J Med 1992;327: 1032-1033.
88. Schifferli J, Leski M, Favre H, Imbach P, Nydegger U, Davies K. High dose intravenous IgG treatment and renal function. Lancet 1991;337:457-458.
89. Vera-Ramirez M, Charlet M, Parry GJ. Recurrent aseptic meningitis complicating intravenous immunoglobulin therapy of chronic inflammatory demyelinating polyradiculopathy. Neurology 1992;42:1636-1637.
90. Oomes PG, van der Meche FG, Kleyweg RP. Liver function disturbances in Guillain-Barré syndrome: a prospective longitudinal study in 100 patients. Dutch Guillain-Barré Study Group. Neurology 1996;46:96-100.
91. Harkness K, Howell SJ, Davies-Jones GA. Encephalopathy associated with intravenous immunoglobulin treatment for Guillain-Barré syndrome [letter]. J Neurol Neurosurg Psychiatry 1996;60:586.
92. Voltz R, Rosen FV, Yousry T, Beck J, Hohlfeld R. Reversible encephalopathy with cerebral vasospasm in a Guillain-Barré syndrome patient treated with intravenous immunoglobulin. Neurology 1996;46:250-251.
93. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994;44:223-226.
94. Tam DA, Morton LD, Stroncek DF, Leshner RT. Neutropenia in a patient receiving intravenous immunoglobulin. J Neuroimmunol 1996;64:175-178.
95. Hamdalla HH, Hawkes CH, Spokes EG, Bamford JM, Goulding PJ. Intravenous immunoglobulin in the Guillain-Barré syndrome. May cause severe adverse skin reactions [letter]. BMJ 1996;313:1399-1400.
96. Whittam LR, Hay RJ, Hughes RAC. Eczematous reactions to human immunoglobulin. Br J Dermatol 1997;137:481-482.
97. Schiff RI. Transmission of viral infection through intravenous immunoglobulin. N Engl J Med 1994;331:1649-1650.